The association between wearable device metrics and clinical outcomes in oncology: A systematic review with evidence synthesis and meta-analysis.

Autor: Kos M; Amsterdam UMC, University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands., Brouwer CG; Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands., van Laarhoven HWM; Amsterdam UMC, University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands., Hopman MTE; Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands., van Oijen MGH; Amsterdam UMC, University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands., Buffart LM; Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands. Electronic address: Laurien.buffart@radboudumc.nl.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2023 May; Vol. 185, pp. 103979. Date of Electronic Publication: 2023 Mar 30.
DOI: 10.1016/j.critrevonc.2023.103979
Abstrakt: Background: The emerging study of wearable devices (WDs) in patients with cancer provides opportunities to harness real-time patient data for predicting clinical outcomes. We conducted a systematic review with best evidence synthesis to examine the association between WD metrics and clinical outcomes in patients with cancer.
Methods: MEDLINE and Embase were searched from inception until June 2022. Risk of bias assessment and best evidence synthesis were performed and, If possible, meta-analysis was conducted.
Results: A total of 34 studies was included. We found moderate-to-strong evidence for associations between circadian rest-activity metrics and OS. Disrupted IConclusion: Meta-analysis was greatly hampered due to heterogeneity and different methodology used between studies. Studies primarily designed to investigate the association between WD metrics and clinical outcomes are warranted.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M.G.H. Van Oijen reports a relationship with Bristol Myers Squibb Co that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory and funding grants. H.W.M. Van Laarhoven reports a relationship with Astellas Pharma Inc that includes: consulting or advisory. H.W.M. Van Laarhoven reports a relationship with Daiichi Sankyo Inc that includes: consulting or advisory. H.W.M. Van Laarhoven reports a relationship with DRAGONFLY Therapeutics Inc that includes: consulting or advisory. H.W.M. Van Laarhoven reports a relationship with Eli Lilly and Company that includes: consulting or advisory and funding grants. H.W.M. Van Laarhoven reports a relationship with Merck & Co Inc that includes: consulting or advisory and funding grants. H.W.M. Van Laarhoven reports a relationship with Novartis that includes: consulting or advisory. H.W.M. Van Laarhoven reports a relationship with Nordic Pharma that includes: consulting or advisory and funding grants. H.W.M. Van Laarhoven reports a relationship with Servier that includes: consulting or advisory and funding grants. H.W.M. Van Laarhoven reports a relationship with Roche that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with Phillips that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with Bayer that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with Dutch Cancer Society that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with Netherlands Organisation for Health Research and Development that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with European Research Council that includes: funding grants. H.W.M. Van Laarhoven reports a relationship with MaagDarmLever Stichting that includes: funding grants. L.M. Buffart reports a relationship with Dutch Research Council that includes: funding grants. L.M. Buffart reports a relationship with Hypatia Inc that includes: funding grants.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: